Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets.

[1]  R. Paschke,et al.  Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial , 2014, The Lancet.

[2]  R. Paschke,et al.  Association between tumor BRAF and RAS mutation status and clinical outcomes in patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) randomized to sorafenib or placebo: sub-analysis of the phase III DECISION trial , 2014 .

[3]  M. Kreissl,et al.  Cabozantinib in progressive medullary thyroid cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Richard J. Lee,et al.  Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. , 2013, Thyroid : official journal of the American Thyroid Association.

[5]  F. Marano,et al.  Histone deacetylase inhibition affects sodium iodide symporter expression and induces 131I cytotoxicity in anaplastic thyroid cancer cells. , 2013, Thyroid : official journal of the American Thyroid Association.

[6]  E. Palmer,et al.  Re-differentiation of radioiodine-refractory BRAF V600E-mutant thyroid carcinoma with dabrafenib: A pilot study. , 2013 .

[7]  J. Franklyn,et al.  Manipulation of PBF/PTTG1IP Phosphorylation Status; a Potential New Therapeutic Strategy for Improving Radioiodine Uptake in Thyroid and Other Tumors , 2013, The Journal of clinical endocrinology and metabolism.

[8]  D. Pfister,et al.  Evaluation of romidepsin for clinical activity and radioactive iodine reuptake in radioactive iodine-refractory thyroid carcinoma. , 2013, Thyroid : official journal of the American Thyroid Association.

[9]  B. Haugen,et al.  Evolving approaches to patients with advanced differentiated thyroid cancer. , 2013, Endocrine reviews.

[10]  M. Schlumberger,et al.  Progress in molecular-based management of differentiated thyroid cancer , 2013, The Lancet.

[11]  M. Xing,et al.  Molecular pathogenesis and mechanisms of thyroid cancer , 2013, Nature Reviews Cancer.

[12]  S. Larson,et al.  Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. , 2013, The New England journal of medicine.

[13]  M. Schlumberger,et al.  Thyroid Cancer 2 Progress in molecular-based management of diff erentiated thyroid cancer , 2013 .

[14]  G. Sonpavde,et al.  Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis. , 2012, Cancer treatment reviews.

[15]  Stephanie L. Lee.  Radioactive iodine therapy , 2012, Current opinion in endocrinology, diabetes, and obesity.

[16]  Thomas Krause,et al.  Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. , 2012, The Lancet. Oncology.

[17]  J. Bishop,et al.  BRAF Mutation in Papillary Thyroid Cancer and Its Value in Tailoring Initial Treatment: A Systematic Review and Meta-Analysis , 2012, Medicine.

[18]  D. Nostrand,et al.  Radioiodine treatment of well-differentiated thyroid cancer , 2012, Endocrine.

[19]  A. Belfiore,et al.  Thyroid cancer development and progression: emerging role of cancer stem cells. , 2012, Minerva endocrinologica.

[20]  M. Ringel,et al.  Modulation of sodium iodide symporter expression and function by LY294002, Akti-1/2 and Rapamycin in thyroid cells. , 2012, Endocrine-related cancer.

[21]  D. Ramies,et al.  Antitumor activity of cabozantinib (XL184) in a cohort of patients (pts) with differentiated thyroid cancer (DTC). , 2012 .

[22]  M. Shah,et al.  Lenvatinib treatment of advanced RAI-refractory differentiated thyroid cancer (DTC): Cytokine and angiogenic factor (CAF) profiling in combination with tumor genetic analysis to identify markers associated with response. , 2012 .

[23]  M. Brown,et al.  Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial , 2012, The Lancet.

[24]  E. Silberstein.  Radioiodine: the classic theranostic agent. , 2012, Seminars in nuclear medicine.

[25]  Y. Youn,et al.  The association of the BRAFV600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer , 2012, Cancer.

[26]  A. Bockisch,et al.  Effects of Rosiglitazone on Radioiodine Negative and Progressive Differentiated Thyroid Carcinoma as Assessed by 124I PET/CT Imaging , 2012, Clinical nuclear medicine.

[27]  M. Cabanillas,et al.  Differentiated Thyroid Cancer: Management of Patients with Radioiodine Nonresponsive Disease , 2012, Journal of thyroid research.

[28]  D. Hayes,et al.  Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements , 2012, Clinical Cancer Research.

[29]  E. Baudin,et al.  Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  G. Pentheroudakis,et al.  Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  A. Bockisch,et al.  Pioglitazone therapy in progressive differentiated thyroid carcinoma , 2012, Nuklearmedizin.

[32]  S. Larson,et al.  Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. , 2011, The Journal of clinical investigation.

[33]  N. Eberhardt,et al.  Antitumor Activity of VB-111, a Novel Antiangiogenic Virotherapeutic, in Thyroid Cancer Xenograft Mouse Models. , 2011, Genes & cancer.

[34]  M. Luster,et al.  Radioiodine for remnant ablation and therapy of metastatic disease , 2011, Nature Reviews Endocrinology.

[35]  J. Franklyn,et al.  Proto-oncogene PBF/PTTG1IP regulates thyroid cell growth and represses radioiodide treatment. , 2011, Cancer research.

[36]  J. Franklyn,et al.  Expression and function of the novel proto-oncogene PBF in thyroid cancer: a new target for augmenting radioiodine uptake. , 2011, The Journal of endocrinology.

[37]  K. Harrington,et al.  Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. , 2011, European journal of endocrinology.

[38]  M. Schlumberger,et al.  A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  D. Jarjoura,et al.  Akt deficiency delays tumor progression, vascular invasion, and distant metastases in a murine model of thyroid cancer , 2011, Oncogene.

[40]  Emma Lundsmith,et al.  Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice , 2011, Proceedings of the National Academy of Sciences.

[41]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[42]  M. Schlumberger,et al.  Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. , 2010, The Journal of clinical endocrinology and metabolism.

[43]  B. Goh,et al.  Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. , 2010, The Lancet. Oncology.

[44]  Radiology,et al.  Clinical Cancer esearch cer Therapy : Clinical se II Study of Daily Sunitinib in FDG-PET – Positive , ne-Refractory Differentiated Thyroid Cancer and astatic Medullary Carcinoma of the Thyroid R Functional Imaging Correlation , 2010 .

[45]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[46]  L. Nasciutti,et al.  MTOR downregulates iodide uptake in thyrocytes. , 2010, The Journal of endocrinology.

[47]  A. Melcher,et al.  The biology of the sodium iodide symporter and its potential for targeted gene delivery. , 2010, Current cancer drug targets.

[48]  P. Hou,et al.  Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways. , 2010, The Journal of clinical endocrinology and metabolism.

[49]  M. Huijberts,et al.  Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. , 2009, European journal of endocrinology.

[50]  Stephanie L. Lee,et al.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[51]  P. Santisteban,et al.  The BRAF V600E Oncogene Induces Transforming Growth Factor β Secretion Leading to Sodium Iodide Symporter Repression and Increased Malignancy in Thyroid Cancer , 2009 .

[52]  J. Franklyn,et al.  A novel mechanism of sodium iodide symporter repression in differentiated thyroid cancer , 2009, Journal of Cell Science.

[53]  M. Shah,et al.  New therapeutic advances in the management of progressive thyroid cancer. , 2009, Endocrine-related cancer.

[54]  B. Jarzab,et al.  13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study , 2009, Thyroid research.

[55]  M. Ladanyi,et al.  Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. , 2009, Cancer research.

[56]  Jiachao Liang,et al.  Phase II trial of sorafenib in metastatic thyroid cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  M. Grever,et al.  Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. , 2009, The Journal of clinical endocrinology and metabolism.

[58]  N. Mitsiades,et al.  Molecular pathology of thyroid cancer: diagnostic and clinical implications. , 2008, Best practice & research. Clinical endocrinology & metabolism.

[59]  G. Brent,et al.  Phosphoinositide-3-kinase inhibition induces sodium/iodide symporter expression in rat thyroid cells and human papillary thyroid cancer cells. , 2008, The Journal of endocrinology.

[60]  Andrea B Troxel,et al.  Phase II trial of sorafenib in advanced thyroid cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  E. Vokes,et al.  Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  A. Pinchera,et al.  BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. , 2008, The Journal of clinical endocrinology and metabolism.

[63]  I. Screpanti,et al.  Notch signaling is involved in expression of thyrocyte differentiation markers and is down-regulated in thyroid tumors. , 2008, The Journal of clinical endocrinology and metabolism.

[64]  L. Bastholt,et al.  Motesanib diphosphate in progressive differentiated thyroid cancer. , 2008, The New England journal of medicine.

[65]  E. Vokes,et al.  Phase 2 study of sunitinib in refractory thyroid cancer , 2008 .

[66]  S. Bates,et al.  Phase I trial of romidepsin, a histone deacetylase inhibitor, given on days one, three and five in patients with thyroid and other advanced cancers , 2008 .

[67]  J. Romijn,et al.  Radioiodine therapy after pretreatment with bexarotene for metastases of differentiated thyroid carcinoma , 2008, Clinical endocrinology.

[68]  S. Filetti,et al.  BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. , 2007, The Journal of clinical endocrinology and metabolism.

[69]  J. Franklyn,et al.  PTTG and PBF repress the human sodium iodide symporter , 2007, Oncogene.

[70]  M. Xing,et al.  Gene methylation in thyroid tumorigenesis. , 2007, Endocrinology.

[71]  P. Hou,et al.  Suppression of BRAF/MEK/MAP Kinase Pathway Restores Expression of Iodide-Metabolizing Genes in Thyroid Cells Expressing the V600E BRAF Mutant , 2007, Clinical Cancer Research.

[72]  Q. Duh,et al.  A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer. , 2006, Surgery.

[73]  E. Mazzaferri.  How beneficial is radioiodine therapy for treating distant metastases from thyroid carcinoma? , 2006, Nature Clinical Practice Endocrinology &Metabolism.

[74]  M. A. García-Cabezas,et al.  The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. , 2006, Endocrine-related cancer.

[75]  Sheue-yann Cheng,et al.  Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[76]  E. Baudin,et al.  Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. , 2006, The Journal of clinical endocrinology and metabolism.

[77]  G. Tell,et al.  Effects of histone acetylation on sodium iodide symporter promoter and expression of thyroid-specific transcription factors. , 2005, Endocrinology.

[78]  J. Franklyn,et al.  Pituitary tumor transforming gene binding factor: a novel transforming gene in thyroid tumorigenesis. , 2005, The Journal of clinical endocrinology and metabolism.

[79]  J. Fagin,et al.  Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. , 2005, Cancer research.

[80]  S. Jhiang,et al.  Inhibition of Heat Shock Protein 90, a Novel RET/PTC1-associated Protein, Increases Radioiodide Accumulation in Thyroid Cells* , 2004, Journal of Biological Chemistry.

[81]  T. Endo,et al.  Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin. , 2004, Endocrinology.

[82]  A. Buescu,et al.  Retinoic acid in patients with radioiodine non-responsive thyroid carcinoma , 2004, Journal of endocrinological investigation.

[83]  J. Fagin,et al.  RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase , 2003, Oncogene.

[84]  P. Ladenson,et al.  Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. , 2003, Cancer research.

[85]  C. Spitzweg,et al.  The sodium iodide symporter: its pathophysiological and therapeutic implications , 2002, Clinical endocrinology.

[86]  P. Santisteban,et al.  PI3K is involved in the IGF-I inhibition of TSH-induced sodium/iodide symporter gene expression. , 2002, Molecular endocrinology.

[87]  H. Müller-Gärtner,et al.  Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[88]  E. D. de Vries,et al.  Differentiated thyroid carcinoma: a polygenic disease. , 2001, Thyroid : official journal of the American Thyroid Association.

[89]  R. Vile,et al.  Clinical review 132: The sodium iodide symporter and its potential role in cancer therapy. , 2001, The Journal of clinical endocrinology and metabolism.

[90]  T. Fojo,et al.  Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. , 2001, The Journal of clinical endocrinology and metabolism.

[91]  N. Carrasco,et al.  Post-transcriptional Regulation of the Sodium/Iodide Symporter by Thyrotropin* , 2001, The Journal of Biological Chemistry.

[92]  Z. Baloch,et al.  Rapid communication: predominant intracellular overexpression of the Na(+)/I(-) symporter (NIS) in a large sampling of thyroid cancer cases. , 2001, The Journal of clinical endocrinology and metabolism.

[93]  M. Yatin,et al.  Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I-symporter gene methylation status. , 1999, The Journal of clinical endocrinology and metabolism.

[94]  M. Santoro,et al.  Human N-ras, TRK-T1, and RET/PTC3 oncogenes, driven by a thyroglobulin promoter, differently affect the expression of differentiation markers and the proliferation of thyroid epithelial cells. , 1999, Oncology research.

[95]  T. Endo,et al.  Increased expression of the sodium/iodide symporter in papillary thyroid carcinomas. , 1998, The Journal of clinical investigation.

[96]  G. D. Vita,et al.  Expression of the RET/PTC1 oncogene impairs the activity of TTF-1 and Pax-8 thyroid transcription factors. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[97]  J. Köhrle,et al.  Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. , 1997, Biochemical and biophysical research communications.

[98]  S. Jhiang,et al.  Expression, exon-intron organization, and chromosome mapping of the human sodium iodide symporter. , 1997, Endocrinology.

[99]  Qing-Rong Liu,et al.  Cloning of the human sodium lodide symporter. , 1996, Biochemical and biophysical research communications.

[100]  N. Carrasco,et al.  Cloning and characterization of the thyroid iodide transporter , 1996, Nature.

[101]  S. M. Seidlin,et al.  Radioactive iodine therapy; effect on functioning metastases of adenocarcinoma of the thyroid. , 1946, Journal of the American Medical Association.